Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Teva Pharmaceutical Industries Ltd (TEVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,423,120
  • Shares Outstanding, K 1,016,000
  • Annual Sales, $ 21,903 M
  • Annual Income, $ 329,000 K
  • 36-Month Beta 0.54
  • Price/Sales 0.96
  • Price/Cash Flow 3.35
  • Price/Book 0.84
  • Price/Earnings ttm 5.02
  • Earnings Per Share ttm 4.33
  • Most Recent Earnings 1.00 on 11/02/17
  • Next Earnings Date 02/08/18
  • Annual Dividend & Yield 0.72 (3.32%)
  • Most Recent Dividend 0.07 on 11/27/17
  • Sectors:

    Medical - Generic Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.33 +43.97%
on 12/13/17
22.64 -2.52%
on 01/12/18
+5.55 (+33.60%)
since 12/12/17
3-Month
10.85 +103.41%
on 11/02/17
22.64 -2.52%
on 01/12/18
+6.92 (+45.68%)
since 10/12/17
52-Week
10.85 +103.41%
on 11/02/17
37.94 -41.83%
on 02/21/17
-11.87 (-34.97%)
since 01/12/17

Most Recent Stories

More News
Teva Announces U.S. FDA Approval of TRISENOX(R) (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved the use of TRISENOX(R) (arsenic trioxide) injection in combination...

TEVA : 22.07 (+1.52%)
Parkinson's Disease Space Again Under Spotlight This Week

Parkinson's Disease emerges a lucrative area in want of curative therapies in the space. To this end, many players work toward launching new treatments in the market.

ADMS : 35.58 (-0.08%)
NVS : 86.65 (+1.14%)
TEVA : 22.07 (+1.52%)
PFE : 36.54 (-0.05%)
AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.

AZN : 35.65 (+0.71%)
TEVA : 22.07 (+1.52%)
AMGN : 185.04 (+1.69%)
GSK : 37.50 (+1.79%)
Today's Research Reports on Stocks to Watch: Novavax, Inc. and Teva Pharmaceutical

NEW YORK, NY / ACCESSWIRE / January 11, 2018 / Novavax shares exploded on Wednesday after the company revealed positive news about its lead vaccine candidate at this year's J.P. Morgan Healthcare Conference....

NVAX : 1.61 (-18.69%)
TEVA : 22.07 (+1.52%)
Orphan Rare Diseases R&D Advancements Increase Novel Therapeutic Options for Drug Development Pipeline

Rare conditions are also known as Orphan diseases which are generally categorized as chronic, degenerative and life-threatening in nature and normally include certain cancers, metabolic conditions, diseases...

PTIE : 7.80 (-8.34%)
DFFN : 1.42 (-5.02%)
GBT : 56.60 (+0.27%)
TEVA : 22.07 (+1.52%)
MBRX : 1.87 (-1.06%)
Medical Device Innovation Continues to Transform Future of Healthcare Sector

The growth in development for addressing healthcare, specifically unmet needs, as well as the ongoing and increasing need for developing the latest therapies and biotech drugs as Baby Boomer generation...

AGEN : 3.87 (-0.26%)
OHRP : 0.33 (+3.13%)
GALT : 5.87 (+6.73%)
ALDR : 17.85 (-0.28%)
BSGM : 1.4700 (unch)
TEVA : 22.07 (+1.52%)
Momenta Reports Positive Top-Line Data on Antibody M281

Momenta reported positive top-line results from a phase I study on M281 wherein the candidate did not show any adverse event, was well tolerated, and decreased circulating IgG levels up to 89%.

MYL : 46.90 (+0.41%)
MNTA : 15.75 (+10.14%)
TEVA : 22.07 (+1.52%)
REGN : 366.96 (-0.35%)
Teva Announces Global License Agreement with Alder BioPharmaceuticals(R) in the Field of Anti-CGRP-Based Therapy

Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that its subsidiary, Teva Pharmaceuticals International GmbH., has signed a global license agreement with Alder BioPharmaceuticals....

TEVA : 22.07 (+1.52%)
Teva to Present at the 36th Annual J.P. Morgan Healthcare Conference

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will host a live audio webcast at the 36th Annual J.P. Morgan Healthcare Conference. Kare Schultz, President & CEO will present on Monday,...

JPM : 112.67 (+1.65%)
TEVA : 22.07 (+1.52%)
Momenta & Mylan to Initiate Trial on Biosimilar of Eylea

Momenta (MNTA), in collaboration with Mylan (MYL), plans to initiate a trial of M710, a proposed biosimilar of leading ophthalmology drug Eylea, in the first half of 2018.

MYL : 46.90 (+0.41%)
MNTA : 15.75 (+10.14%)
TEVA : 22.07 (+1.52%)
REGN : 366.96 (-0.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended...

See More

Key Turning Points

2nd Resistance Point 23.11
1st Resistance Point 22.59
Last Price 22.07
1st Support Level 21.60
2nd Support Level 21.13

See More

52-Week High 37.94
Fibonacci 61.8% 27.59
Fibonacci 50% 24.40
Last Price 22.07
Fibonacci 38.2% 21.20
52-Week Low 10.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.